Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio M. Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteyza; Rafael F. Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferrá; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi

doi:10.1056/nejmoa1506002

Abstract

This is the authors' abstract. We don't add key points for this paper.

The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD-free survival and relapse-free survival was higher with ATG. (Funded by the Neovii Biotech and the European Society for Blood and Marrow Transplantation; ClinicalTrials.gov number, NCT00678275.).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kröger et al. (2016) studied this question.

synapsesocial.com/papers/69d9392c7fca1f84ab68464a https://doi.org/10.1056/nejmoa1506002

View Full Paper

Ask AI

Bookmark

Share

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Abstract

Ask about this paper

Discussion

Cite This Study

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading